ADS-ADEA 2015* Weight loss with liraglutide 3.0 mg is associated with improved health-related quality of life (HRQoL) and treatment satisfaction in overweight or obese adults with type 2 diabetes (T2D): The SCALE Diabetes randomised, double-blind, placebo-controlled 56-week trial (#304)
2:00 PM
Liraglutide 3.0 mg: weight-loss dependent and independent effects (#305)
2:00 PM
Efficacy and safety of liraglutide 3.0 mg and 1.8 mg in weight loss responders from overweight/obese adults with type 2 diabetes (T2D): A subgroup analysis of the SCALE Diabetes trial (#306)
2:00 PM
Primary care based transition to insulin to improve outcomes in type 2 diabetes: Results of the Stepping Upcluster randomised controlled trial (#307)
2:00 PM
Glucose-lowering medication prescription profile outside W Europe and N America from 2006-2012: evidence from multiple clinical sites (#308)
2:00 PM
Cardiovascular therapy in people with diabetes outside West Europe and North America: evidence from multiple clinical sites (#309)
2:00 PM
Cardiovascular safety of liraglutide: meta-analysis of major adverse cardiovascular events (MACE) across weight management and T2D development programs (#310)
2:00 PM
“It is definitely a game changer”: Closed Loop technology in the home experienced by adults with type 1 diabetes (#311)
2:00 PM
Continuous Intra-Peritoneal Insulin Infusion (CIPII) using the Diaport external pump system, in type 1 diabetes patients with suboptimal control– A case series from an Australian Tertiary Centre (#312)
2:00 PM
Role Of Oral Cholecalciferol As Adjuvant Therapy In Type 1 Diabetes Mellitus: Randomized Controlled Trial (#313)
2:00 PM
Humulin R (U-500) and effects on HbA1c and weight in patients with severe insulin resistance in Tasmania. (#314)
2:00 PM
Comparing a basal-bolus booster insulin regimen to standard care for inpatient hyperglycaemia in a major tertiary referral centre (#315)
2:00 PM